专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07449557B2 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy 失效
标题翻译： α（2）巨球蛋白和抗原分子的免疫治疗复合物
公开(公告)号：US07449557B2
公开(公告)日：2008-11-11
申请号：US09873403
申请日：2001-06-04
申请人： Pramod K. Srivastava , Robert J. Binder
发明人： Pramod K. Srivastava , Robert J. Binder
IPC分类号： C07K17/00
CPC分类号： C07K14/8107 , A61K39/0008 , A61K39/0011 , A61K39/385 , A61K2039/5152 , A61K2039/5156 , A61K2039/6031 , A61K2039/622 , C07K2319/00
摘要： The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
摘要翻译：本发明涉及与用于免疫治疗的抗原性分子相关的α（2）巨球蛋白的复合物。本发明涉及在免疫疾病，增殖性疾病和感染性疾病的诊断和治疗中使用这些组合物的方法。

2. 发明授权

US07179462B2 α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof 有权
标题翻译： α（2）巨球蛋白受体作为热休克蛋白受体及其应用
公开(公告)号：US07179462B2
公开(公告)日：2007-02-20
申请号：US09750972
申请日：2000-12-28
申请人： Pramod K. Srivastava , Robert J. Binder
发明人： Pramod K. Srivastava , Robert J. Binder
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A61K35/14 , A61K38/00 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C07K14/70596 , C07K16/2896 , G01N33/92 , G01N2333/705 , G01N2500/02
摘要： The present invention relates to the use of alpha (2) macroglobulin (“α2M”) receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other molecules that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the α2M receptor, and modulate the interaction of the α2M receptor with its ligand, such as HSPs, and methods for using compositions comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
摘要翻译：本发明涉及α（2）巨球蛋白（“α2M”）受体作为热休克蛋白受体，表达与HSP结合的α2M受体的细胞，以及结合α2M受体-HSP复合物的抗体和其他分子。本发明还涉及筛选测定以鉴定与α2M受体相互作用并调节α2M受体与其配体如HSP的相互作用的化合物，以及使用包含α2M受体序列的组合物用于诊断和治疗免疫的方法疾病，增殖性疾病和感染性疾病。

3. 发明授权

US06797480B1 Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents 失效
标题翻译：热休克/应激蛋白细胞表面受体的纯化及其作为免疫治疗剂的用途
公开(公告)号：US06797480B1
公开(公告)日：2004-09-28
申请号：US09411075
申请日：1999-10-04
申请人： Pramod K. Srivastava
发明人： Pramod K. Srivastava
IPC分类号： G01N3353
CPC分类号： G01N33/6845 , G01N33/68 , Y02A50/55
摘要： The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.
摘要翻译：本发明涉及热休克蛋白（HSP）的受体，例如gp96，Hsp70和Hsp90。热休克受体与抗原呈递细胞亚群如巨噬细胞和树突状细胞的细胞膜相关。本发明涉及热休克蛋白受体阳性细胞，热休克蛋白受体蛋白和热休克蛋白受体基因在筛选分子以调节热休克蛋白水平或活性的能力的方法中的应用。

4. 发明授权

US06455048B1 Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes 失效
标题翻译：用hsp70肽复合物预防原发性和转移性肿瘤疾病
公开(公告)号：US06455048B1
公开(公告)日：2002-09-24
申请号：US09440173
申请日：1999-11-15
申请人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K39385
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

5. 发明授权

US06399069B1 Prevention of infectious diseases with hsp70-peptide complexes 失效
标题翻译：用hsp70肽复合物预防传染病
公开(公告)号：US06399069B1
公开(公告)日：2002-06-04
申请号：US09439684
申请日：1999-11-15
申请人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K39385
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

6. 发明授权

US06383493B1 Methods and compositions for eliciting an immune response with hsp70-peptide complexes 有权
标题翻译：用hsp70-肽复合物引发免疫应答的方法和组合物
公开(公告)号：US06383493B1
公开(公告)日：2002-05-07
申请号：US09440171
申请日：1999-11-15
申请人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K39385
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes-of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答的方法和组合物以及预防和治疗原发性和转移性肿瘤性疾病和感染性疾病。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合到抗原分子的hsps复合物敏化的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

7. 发明授权

US06379672B1 Prevention of infectious diseases with gp96-peptide complexes 失效
标题翻译：用gp96肽复合物预防传染病
公开(公告)号：US06379672B1
公开(公告)日：2002-04-30
申请号：US09439683
申请日：1999-11-15
申请人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K39385
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原性/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

8. 发明授权

US6048530A Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens 失效
标题翻译：应激蛋白 - 肽复合物作为针对细胞内病原体的预防和治疗性疫苗
公开(公告)号：US6048530A
公开(公告)日：2000-04-11
申请号：US704727
申请日：1997-06-19
申请人： Pramod K. Srivastava
发明人： Pramod K. Srivastava
IPC分类号： A61K39/00 , A61K39/002 , A61K39/02 , A61K39/118 , A61K39/12 , A61K39/295 , A61K39/385 , A61K39/39 , A61K47/48 , A61P31/00 , A61P37/04 , C07K14/47 , C07K14/52 , C07K17/00 , C07K17/02 , A61K39/395
CPC分类号： A61K39/39 , A61K39/12 , A61K39/385 , A61K47/4833 , C07K14/47 , C07K17/02 , A61K2039/55522 , A61K2039/57 , A61K2039/6043 , A61K2039/622 , C12N2760/16122 , Y10S436/823 , Y10S530/806
摘要： Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes.
摘要翻译： PCT No.PCT / US95 / 03311 Sec。 371日期：1997年6月19日 102（e）日期1996年6月19日PCT 1995年3月16日PCT公布。 WO95 / 24923 PCT公开号日期1995年9月21日公开是一种含有应激蛋白 - 肽复合物的疫苗，当向哺乳动物施用时，它们可以起作用于在哺乳动物中引发针对感染了预选细胞内病原体的细胞的细胞毒性T细胞应答。还公开了制备和施用含有这种应激蛋白 - 肽复合物的疫苗的方法。

9. 发明授权

US6017544A Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine 失效
标题翻译：包含针对癌症和细胞因子的免疫原性应激蛋白 - 肽复合物的组合物
公开(公告)号：US6017544A
公开(公告)日：2000-01-25
申请号：US61365
申请日：1998-04-16
申请人： Pramod K. Srivastava
发明人： Pramod K. Srivastava
IPC分类号： C12P21/00 , A61K38/00 , A61K38/19 , A61K38/21 , A61K39/00 , A61K45/00 , A61P35/00 , A61P35/02 , A61P37/04 , C07K14/47 , C07K14/82 , C07K19/00 , A61K35/12 , A61K39/385
CPC分类号： A61K39/0011 , A61K38/19 , A61K39/0005 , C07K14/4702 , A61K2039/6043 , A61K2039/622 , A61K39/00
摘要： Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex along with a cytokine to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the Hsp70-peptide, Hsp90-peptide and gp96-peptide complexes.
摘要翻译：公开了抑制哺乳动物肿瘤增殖的方法。该方法包括以下步骤：（a）从先前从哺乳动物中去除的肿瘤细胞中分离应激蛋白 - 肽复合物，和（b）向哺乳动物施用分离的应激蛋白 - 肽复合物以及细胞因子以在哺乳动物中刺激针对分离复合物的肿瘤的免疫应答。在本发明实践中具有特别实用性的应激蛋白 - 肽复合物包括Hsp70-肽，Hsp90-肽和gp96-肽复合物。

10. 发明授权

US6007821A Method and compositions for the treatment of autoimmune disease using heat shock proteins 失效
标题翻译：用热休克蛋白治疗自身免疫性疾病的方法和组合物
公开(公告)号：US6007821A
公开(公告)日：1999-12-28
申请号：US951789
申请日：1997-10-16
申请人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： C12N15/09 , A61K35/12 , A61K38/00 , A61K38/17 , A61P1/04 , A61P1/16 , A61P3/10 , A61P13/12 , A61P29/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K14/47 , A61K39/00 , A01N37/18 , A61K39/385 , C07K14/435
CPC分类号： A61K38/1709 , Y10S424/81 , Y10S514/825 , Y10S514/866 , Y10S514/903 , Y10S530/806 , Y10S530/827 , Y10S530/868
摘要： The invention relates to methods and compositions for the treatment of autoimmune disease. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, are disclosed. Immunotherapeutic methods for administering the hsp-containing compositions are disclosed. Furthermore, methods for preventing rejection of organs transplanted to treat autoimmune disease are disclosed. The disclosed methods are useful for treating a variety of autoimmune diseases, including insulin dependent diabetes mellitus.
摘要翻译：本发明涉及用于治疗自身免疫疾病的方法和组合物。具体地，公开了包含热休克蛋白的组合物，包括gp96，hsp90和hsp70。公开了用于施用含hsp的组合物的免疫治疗方法。此外，公开了用于防止移植以治疗自身免疫疾病的器官的排斥的方法。所公开的方法可用于治疗多种自身免疫性疾病，包括胰岛素依赖性糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式